180
Views
40
CrossRef citations to date
0
Altmetric
Original article

Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy

, , , , , & show all
Pages 177-183 | Received 01 Nov 2004, Accepted 27 Jan 2005, Published online: 08 Jul 2009

References

  • Davis PH, Dawson JD, Riley WA, Lauer RM. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation. 2001;104:2815–2819.
  • Chambless LE, Folsom AR, Davis V, Sharrett R, Heiss G, Sorlie P, et al. Risk factors for progression of common carotid atherosclerosis: The Atherosclerosis Risk in Communities Study, 1987-1998. Am J Epidemiol. 2002;155:38–47.
  • Agewall S, Fagerberg B, Berglund G, Schmidt C, Wendelhag I, Wikstrand J. Multiple risk intervention trial in high risk hypertensive men: Comparison of ultrasound intima-media thickness and clinical outcome during 6 years of follow-up. J Intern Med. 2001;249:305–314.
  • Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb. 1991;11:1245–1249.
  • Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Correlation between common carotid arterial wall thickness and ischemic stroke in patients with type 2 diabetes mellitus. Metabolism. 2002;51: 244–247.
  • O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SKJ. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999;340:14–22.
  • Mancini GB. Carotid intima-media thickness as a measure of vascular target organ damage. Curr Hypertens Rep. 2000;2:71–77.
  • Zanchetti A. The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing. Curr Hypertens Rep. 2001;3:350–359.
  • Schiffrin EL. Effects of antihypertensive drugs on vascular remodeling: Do they predict outcome in response to antihypertensive therapy? Curr Opin Nephrol Hypertens. 2001;10:617–624.
  • Park JB, Schiffrin EL. Effects of antihypertensive therapy on hypertensive vascular disease. Curr Hypertens Rep. 2000;2:280–288.
  • Schiffrin EL. Vascular changes in hypertension in response to drug treatment: Effects of angiotensin receptor blockers. Can J Cardiol. 2002;18 Suppl A:15A–18A.
  • Stanton AV, Chapman JN, Mayet J, Sever PS, Poulter NR, Hughes AD, et al. Effects of blood pressure lowering with amlodipine or lisinopril on vascular structure of the common carotid artery. Chin Sci (Lond ). 2001;101:455–464.
  • Benetos A, Gautier S, Lafleche A, Topouchian J, Frangin G, Girerd X, et al. Blockade of angiotensin II type 1 receptors: Effect on carotid and radial artery structure and function in hypertensive humans. J Vasc Res. 2000;37:8–15.
  • Simon A, Gariepy J, Moyse D, Levenson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation. 2001;103:2949–2954.
  • Hedblad B, Wikstrand J, Janzon L, Wedel H, Berglund G. Low-dose metoprolol CR/XL and fluvastatin slow progres-sion of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (B CAPS) . Circulation. 2001;103:1721–1726.
  • Ludwig M, Stapff M, Ribeiro A, Fritschka E, Tholl U, Smith RD, et al. Comparison of the effects of losartan and atenolol on common carotid artery intima-media thickness in patients with hypertension: Results of a 2-year, double-blind, randomized, controlled study. Chin Ther. 2002;24: 1175–1193.
  • Schiffrin EL. Effect of antihypertensive therapy on small artery structure in hypertensive patients [letter; comment]. Hypertension. 1995;26:716–718.
  • Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension. 1996;27(3 Pt 1):371–376.
  • Marceau M, Kouame N, Lacourciere Y, Cleroux J. Vascular structure in the forearm and calf after 6 months of angiotensin converting enzyme inhibition in elderly hypertensive subjects with left ventricular hypertrophy. J Hypertens. 1998; 16:673–679.
  • Takata M, Ueno H, Hirai T, Oh-hashi S, Yasumoto K, Inoue H. Time course of the effects of temocapril on cardiovascular structure and function in patients with essential hypertension. J Cardiovasc Pharmacol. 1999; 34:561–566.
  • Schiffrin EL, Park JB, Intengan HD, Touyz R1\4. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan [In Process Citation]. Circulation. 2000;101: 1653–1659.
  • Schiffrin EL, Park JB, Pu Q. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function. J Hypertens. 2002;20:71–78.
  • Olsen MH, Fossum E, Hjerkinn E, Wachtell K, Hoieggen A, Nesbitt SD, et al. Relative influence of insulin resistance versus blood pressure on vascular changes in longstanding hypertension. ICARUS, a LIFE substudy. J Hypertens. 2000;18:75–81.
  • Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U, et al. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study [In Process Citation]. Hypertension. 1998;32: 989–997.
  • Howard G, Sharrett AR, Heiss G, Evans GW, Chambless LE, Riley WA, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. ARIC Investigators. Stroke. 1993;24:1297–1304.
  • Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347–504.
  • Cooper KE, Edholm OG, Mottram RF. The blood flow in skin and muscle of the human forearm. J Physiol. 1954;128:258–267.
  • Palmieri V, Dahlof B, DeQuattro V, Sharpe N, Bella JN, de Simone G, et al. Reliability of echocardiographic assessment of left ventricular structure and function: The PRESERVE study. Prospective Randomized Study Evaluating Regression of Ventricular Enlargement [see comments]. J Am Coll Cardiol. 1999;34:1625–1632.
  • Olsen MH, Wachtell K, Hermann KL, Frandsen E, Dige-Petersen H, Rokkedal J, et al. Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension. Am Heart J. 2002; 144:530–537.
  • O'Rourke ME, Yaginuma T, Avolio AP. Physiological and pathophysiological implications of ventricular/vascular cou-pling. Ann Biomed Eng. 1984;12:119–134.
  • Roman MJ, Ganau A, Saba PS, Pini R, Pickering TG, Devereux RB. Impact of arterial stiffening on left ventricular structure. Hypertension. 2000;36:489–494.
  • Scuteri A, Chen CH, Yin FC, Chih-Tai T, Spurgeon HA, Lakatta EG. Functional correlates of central arterial geo-metric phenotypes. Hypertension. 2001;38:1471–1475.
  • Buus CL, Pourageaud F, Fazzi GE, Janssen G, Mulvany MJ, De Mey JG. Smooth muscle cell changes during flow-related remodeling of rat mesenteric resistance arteries. Circ Res. 2001;89:180–186.
  • Fridez P, Rachev A, Meister JJ, Hayashi K, Stergiopulos N. Model of geometrical and smooth muscle tone adaptation of carotid artery subject to step change in pressure. Am J Physiol Heart Circ Physiol. 2001;280:H2752–H2760.
  • Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Chin Invest. 1994;94:978–984.
  • Brilla CG, Scheer C, Rupp H. Renin-angiotensin system and myocardial collagen matrix: Modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J Hypertens Suppl. 1997;15:S13–S19.
  • Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD, et al. Long term treatment with losartan vs. atenolol improves insulin sensitivity in hypertension. ICARUS, a LIFE Substudy. J Hypertens. 2005;23: 891–898.
  • Christensen KL, Mulvany MJ. Vasodilatation, not hypoten-sion, improves resistance vessel design during treatment of essential hypertension: A literature survey. J Hypertens. 2001;19:1001–1006.
  • Zanchetti A, Rosei EA, Dal Palu C, Leonetti G, Magnani B, Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS): Results of long-term rando-mized treatment with either verapamil or chlorthalidone on carotid intima-media thickness. J Hypertens. 1998;16: 1667–1676.
  • Touboul PJ, Elbaz A, Koller C, Lucas C, Adrai V, Chedru F, et al. Common carotid artery intima-media thickness and brain infarction: The Etude du Profil Genetique de l'Infarctus Cerebral (GENIC) case-control study. The GENIC Investigators. Circulation. 2000;102:313–318.
  • Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hyperten-sion study (LIFE): A randomised trial against atenolol. Lancet. 2002;359:995–1003.
  • Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E, et al. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint reduction in hypertension. J Hypertens. 2000;18:1129–1138.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.